at-7519 has been researched along with Neoplasms* in 5 studies
4 review(s) available for at-7519 and Neoplasms
Article | Year |
---|---|
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Cyclin-dependent kinase 9 (CDK9), which regulates transcriptional elongation, is an attractive therapeutic target for many cancers, especially for cancers driven by transcriptional dysregulation. In particular, CDK9 promotes RNA polymerase II pause/release, a rate-limiting step in normal transcriptional regulation that is frequently dysregulated in cancers. Emerging evidence indicates that selective CDK9 inhibition or degradation may provide a therapeutic benefit against certain cancers. Indeed, the development of CDK9 modulators (inhibitors and degraders) has attracted great attention, with several molecules currently under clinical development. This review provides an overview of recent advances in CDK9 modulators in general, with special emphasis on compounds under clinical evaluation and new emerging strategies, such as proteolysis targeting chimeras (PROTACs). Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Cyclin-Dependent Kinase 9; Drug Development; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary | 2020 |
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.
Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S- and M-phases of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is critically associated with tumor growth in multiple cancer types. Although the role of CDK2 in tumorigenesis has been controversial, emerging evidence proposes that selective CDK2 inhibition may provide a therapeutic benefit against certain tumors, and it continues to appeal as a strategy to exploit in anticancer drug development. Several small-molecule CDK2 inhibitors have progressed to the clinical trials. However, a CDK2-selective inhibitor is yet to be discovered. Here, we discuss the latest understandings of the role of CDK2 in normal and cancer cells, review the core pharmacophores used to target CDK2, and outline strategies for the rational design of CDK2 inhibitors. We attempt to provide an outlook on how CDK2-selective inhibitors may open new avenues for cancer therapy. Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclin-Dependent Kinase 2; Drug Design; Humans; Neoplasms; Protein Binding; Protein Conformation; Protein Kinase Inhibitors | 2019 |
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
There are around 20 Cyclin-dependent kinases (CDKs) known till date, and various research groups have reported their role in different types of cancer. The X-ray structures of some CDKs especially CDK2 was exploited in the past few years, and several inhibitors have been found, e.g., flavopiridol, indirubicin, roscovitine, etc., but due to the specificity issues of these inhibitors (binding to all CDKs), these were called as pan inhibitors. The revolutionary outcome of palbociclib in 2015 as CDK4/6 inhibitor added a new charm to the specific inhibitor design for CDKs. Computer-aided drug design (CADD) tools added a benefit to the design and development of new CDK inhibitors by studying the binding pattern of the inhibitors to the ATP binding domain of CDKs. Herein, we have attempted a comparative analysis of structural differences between several CDKs ATP binding sites and their inhibitor specificity by depicting the important ligand-receptor interactions for a particular CDK to be targeted. This perspective provides futuristic implications in the design of inhibitors considering the spatial features and structural insights of the specific CDK. Topics: Amino Acid Sequence; Animals; Computer-Aided Design; Crystallography, X-Ray; Cyclin-Dependent Kinases; Drug Design; Humans; Models, Molecular; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Sequence Alignment | 2017 |
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs.
Sustained proliferative capacity is a hallmark of cancer. In mammalian cells proliferation is controlled by the cell cycle, where cyclin-dependent kinases (CDKs) regulate critical checkpoints. CDK4 and CDK6 are considered highly validated anticancer drug targets due to their essential role regulating cell cycle progression at the G1 restriction point. This review provides an overview of recent advances on cyclin dependent kinase inhibitors in general with special emphasis on CDK4 and CDK6 inhibitors and compounds under clinical evaluation. Chemical structures, structure activity relationships, and relevant preclinical properties will be described. Topics: Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinase Inhibitor Proteins; Humans; Neoplasms | 2015 |
1 other study(ies) available for at-7519 and Neoplasms
Article | Year |
---|---|
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly 2 decades due to their widely varied and critical functions within the cell. Recently CDK9 has emerged as a druggable target for the development of cancer therapeutics. CDK9 plays a crucial role in transcription regulation; specifically, CDK9 mediated transcriptional regulation of short-lived antiapoptotic proteins is critical for the survival of transformed cells. Focused chemical libraries based on a plethora of scaffolds have resulted in mixed success with regard to the development of selective CDK9 inhibitors. Here we review the regulation of CDK9, its cellular functions, and common core structures used to target CDK9, along with their selectivity profile and efficacy in vitro and in vivo. Topics: Animals; Cyclin-Dependent Kinase 9; Drug Discovery; Flavonoids; Humans; Macrocyclic Compounds; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Triazines | 2016 |